CN101410174A - 一种用于生产基于乳化的微观粒子的方法 - Google Patents
一种用于生产基于乳化的微观粒子的方法 Download PDFInfo
- Publication number
- CN101410174A CN101410174A CNA2004800084088A CN200480008408A CN101410174A CN 101410174 A CN101410174 A CN 101410174A CN A2004800084088 A CNA2004800084088 A CN A2004800084088A CN 200480008408 A CN200480008408 A CN 200480008408A CN 101410174 A CN101410174 A CN 101410174A
- Authority
- CN
- China
- Prior art keywords
- solvent
- mutually
- agent
- emulsion
- equipment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 89
- 239000000839 emulsion Substances 0.000 title claims abstract description 82
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 50
- 239000011859 microparticle Substances 0.000 title abstract 4
- 239000002245 particle Substances 0.000 claims abstract description 105
- 239000000463 material Substances 0.000 claims abstract description 45
- 238000012856 packing Methods 0.000 claims abstract description 34
- 239000013043 chemical agent Substances 0.000 claims abstract description 20
- 239000002904 solvent Substances 0.000 claims description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 35
- 239000003960 organic solvent Substances 0.000 claims description 26
- 239000003381 stabilizer Substances 0.000 claims description 25
- 239000011521 glass Substances 0.000 claims description 23
- 239000011324 bead Substances 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 19
- -1 pottery Substances 0.000 claims description 18
- 229920000642 polymer Polymers 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 14
- 238000004945 emulsification Methods 0.000 claims description 13
- 230000003213 activating effect Effects 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 229910001220 stainless steel Inorganic materials 0.000 claims description 11
- 239000010935 stainless steel Substances 0.000 claims description 11
- 239000002184 metal Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 239000002537 cosmetic Substances 0.000 claims description 8
- 239000000049 pigment Substances 0.000 claims description 8
- 239000004014 plasticizer Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000003102 growth factor Substances 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 229920003023 plastic Polymers 0.000 claims description 6
- 239000004033 plastic Substances 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 4
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 4
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims description 4
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 4
- 102000015696 Interleukins Human genes 0.000 claims description 4
- 108010063738 Interleukins Proteins 0.000 claims description 4
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims description 4
- 229920000954 Polyglycolide Polymers 0.000 claims description 4
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- 239000000853 adhesive Substances 0.000 claims description 4
- 230000001070 adhesive effect Effects 0.000 claims description 4
- 239000003905 agrochemical Substances 0.000 claims description 4
- 230000003444 anaesthetic effect Effects 0.000 claims description 4
- 239000000730 antalgic agent Substances 0.000 claims description 4
- 230000003178 anti-diabetic effect Effects 0.000 claims description 4
- 230000001387 anti-histamine Effects 0.000 claims description 4
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 4
- 230000002924 anti-infective effect Effects 0.000 claims description 4
- 230000000078 anti-malarial effect Effects 0.000 claims description 4
- 239000003146 anticoagulant agent Substances 0.000 claims description 4
- 229940127219 anticoagulant drug Drugs 0.000 claims description 4
- 239000001961 anticonvulsive agent Substances 0.000 claims description 4
- 239000003472 antidiabetic agent Substances 0.000 claims description 4
- 239000002519 antifouling agent Substances 0.000 claims description 4
- 229940121375 antifungal agent Drugs 0.000 claims description 4
- 239000003429 antifungal agent Substances 0.000 claims description 4
- 239000000739 antihistaminic agent Substances 0.000 claims description 4
- 239000003430 antimalarial agent Substances 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 239000003139 biocide Substances 0.000 claims description 4
- 239000003114 blood coagulation factor Substances 0.000 claims description 4
- 239000002327 cardiovascular agent Substances 0.000 claims description 4
- 229940125692 cardiovascular agent Drugs 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 230000003013 cytotoxicity Effects 0.000 claims description 4
- 231100000135 cytotoxicity Toxicity 0.000 claims description 4
- 239000000975 dye Substances 0.000 claims description 4
- OBNCKNCVKJNDBV-UHFFFAOYSA-N ethyl butyrate Chemical compound CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 235000013373 food additive Nutrition 0.000 claims description 4
- 239000002778 food additive Substances 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 239000000446 fuel Substances 0.000 claims description 4
- 230000002607 hemopoietic effect Effects 0.000 claims description 4
- 230000002363 herbicidal effect Effects 0.000 claims description 4
- 239000004009 herbicide Substances 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 229960001438 immunostimulant agent Drugs 0.000 claims description 4
- 239000003022 immunostimulating agent Substances 0.000 claims description 4
- 230000003308 immunostimulating effect Effects 0.000 claims description 4
- 239000003018 immunosuppressive agent Substances 0.000 claims description 4
- 239000012678 infectious agent Substances 0.000 claims description 4
- 239000000976 ink Substances 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 239000003605 opacifier Substances 0.000 claims description 4
- 239000003973 paint Substances 0.000 claims description 4
- 239000000575 pesticide Substances 0.000 claims description 4
- 229920001432 poly(L-lactide) Polymers 0.000 claims description 4
- 239000004633 polyglycolic acid Substances 0.000 claims description 4
- 229920006324 polyoxymethylene Polymers 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- 229950008882 polysorbate Drugs 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 238000007639 printing Methods 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 239000003380 propellant Substances 0.000 claims description 4
- 239000012744 reinforcing agent Substances 0.000 claims description 4
- 235000013599 spices Nutrition 0.000 claims description 4
- 239000003270 steroid hormone Substances 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 3
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 claims description 3
- 239000003125 aqueous solvent Substances 0.000 claims description 3
- 239000004744 fabric Substances 0.000 claims description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 1
- 150000002905 orthoesters Chemical class 0.000 claims 1
- 238000009826 distribution Methods 0.000 abstract description 14
- 239000003124 biologic agent Substances 0.000 abstract description 6
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 239000012071 phase Substances 0.000 description 50
- 238000005516 engineering process Methods 0.000 description 30
- 238000005086 pumping Methods 0.000 description 16
- 239000004005 microsphere Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- 239000012530 fluid Substances 0.000 description 10
- 239000003995 emulsifying agent Substances 0.000 description 7
- 238000011049 filling Methods 0.000 description 7
- 230000001804 emulsifying effect Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229920002988 biodegradable polymer Polymers 0.000 description 5
- 239000004621 biodegradable polymer Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 4
- 239000004810 polytetrafluoroethylene Substances 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 3
- 208000034189 Sclerosis Diseases 0.000 description 3
- 229950002007 estradiol benzoate Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 102220042174 rs141655687 Human genes 0.000 description 3
- 102220076495 rs200649587 Human genes 0.000 description 3
- 102220043159 rs587780996 Human genes 0.000 description 3
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- RRDBGKFTNJDTBK-WAJSLEGFSA-N OC(=O)C1=CC=CC=C1.OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)O)[C@@H]4[C@@H]3CCC2=C1 Chemical class OC(=O)C1=CC=CC=C1.OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)O)[C@@H]4[C@@H]3CCC2=C1 RRDBGKFTNJDTBK-WAJSLEGFSA-N 0.000 description 2
- 238000010923 batch production Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000010237 hybrid technique Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- AYHOQSGNVUZKJA-UHFFFAOYSA-N [B+3].[B+3].[B+3].[B+3].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] Chemical compound [B+3].[B+3].[B+3].[B+3].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] AYHOQSGNVUZKJA-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 150000002159 estradiols Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000010363 phase shift Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000001869 rapid Effects 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 239000005368 silicate glass Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 230000005514 two-phase flow Effects 0.000 description 1
- 239000010913 used oil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
- B01F23/40—Mixing liquids with liquids; Emulsifying
- B01F23/41—Emulsifying
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
- B01F25/40—Static mixers
- B01F25/45—Mixers in which the materials to be mixed are pressed together through orifices or interstitial spaces, e.g. between beads
- B01F25/452—Mixers in which the materials to be mixed are pressed together through orifices or interstitial spaces, e.g. between beads characterised by elements provided with orifices or interstitial spaces
- B01F25/4524—Mixers in which the materials to be mixed are pressed together through orifices or interstitial spaces, e.g. between beads characterised by elements provided with orifices or interstitial spaces the components being pressed through foam-like inserts or through a bed of loose bodies, e.g. balls
- B01F25/45241—Mixers in which the materials to be mixed are pressed together through orifices or interstitial spaces, e.g. between beads characterised by elements provided with orifices or interstitial spaces the components being pressed through foam-like inserts or through a bed of loose bodies, e.g. balls through a bed of balls
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
- B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
- B01J2/06—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a liquid medium
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/12—Powdering or granulating
- C08J3/14—Powdering or granulating by precipitation from solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Polymers & Plastics (AREA)
- Dispersion Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Biochemistry (AREA)
Abstract
Description
Claims (41)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46186003P | 2003-04-10 | 2003-04-10 | |
US60/461,860 | 2003-04-10 | ||
PCT/US2004/011485 WO2005003180A2 (en) | 2003-04-10 | 2004-04-12 | A method for the production of emulsion-based micro particles |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110028030XA Division CN102166192B (zh) | 2003-04-10 | 2004-04-12 | 一种用于生产基于乳化的微观粒子的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101410174A true CN101410174A (zh) | 2009-04-15 |
CN101410174B CN101410174B (zh) | 2011-04-06 |
Family
ID=33563700
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110028030XA Expired - Lifetime CN102166192B (zh) | 2003-04-10 | 2004-04-12 | 一种用于生产基于乳化的微观粒子的方法 |
CN2004800084088A Expired - Lifetime CN101410174B (zh) | 2003-04-10 | 2004-04-12 | 一种用于生产基于乳化的微观粒子的方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110028030XA Expired - Lifetime CN102166192B (zh) | 2003-04-10 | 2004-04-12 | 一种用于生产基于乳化的微观粒子的方法 |
Country Status (10)
Country | Link |
---|---|
US (2) | US8916196B2 (zh) |
EP (2) | EP2548550A1 (zh) |
JP (3) | JP2007515392A (zh) |
CN (2) | CN102166192B (zh) |
AU (1) | AU2004253853B2 (zh) |
BR (1) | BRPI0409032A (zh) |
CA (1) | CA2516107C (zh) |
ES (1) | ES2427092T3 (zh) |
PT (1) | PT1615959E (zh) |
WO (1) | WO2005003180A2 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102985175A (zh) * | 2009-12-22 | 2013-03-20 | 赢创德固赛有限公司 | 用于制备微粒的基于乳液的工艺以及供所述工艺使用的工作头组件 |
US8900636B2 (en) | 2003-07-23 | 2014-12-02 | Evonik Corporation | Controlled release compositions |
CN111050809A (zh) * | 2017-07-10 | 2020-04-21 | 百深公司 | 孵育液体和灭活病毒的方法 |
CN111051381A (zh) * | 2017-09-03 | 2020-04-21 | 赢创运营有限公司 | 用于增材制造的生物相容聚合物粉末 |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0409032A (pt) * | 2003-04-10 | 2006-05-02 | Pr Pharmaceuticals | método para a produção de micropartìculas à base de emulsão |
US20070207211A1 (en) * | 2003-04-10 | 2007-09-06 | Pr Pharmaceuticals, Inc. | Emulsion-based microparticles and methods for the production thereof |
US8871269B2 (en) * | 2003-07-15 | 2014-10-28 | Evonik Corporation | Method for the preparation of controlled release formulations |
DE102006013531A1 (de) * | 2006-03-24 | 2007-09-27 | Lts Lohmann Therapie-Systeme Ag | Polylactid-Nanopartikel |
US10092524B2 (en) | 2008-06-11 | 2018-10-09 | Edge Therapeutics, Inc. | Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage |
EP2198302B1 (en) | 2007-09-27 | 2017-09-27 | Samyang Biopharmaceuticals Corporation | Sol-gel phase-reversible hydrogel templates and uses thereof |
US9090737B2 (en) * | 2007-11-13 | 2015-07-28 | Surmodics, Inc. | Viscous terpolymers as drug delivery platform |
US8133861B2 (en) | 2008-02-29 | 2012-03-13 | Alseres Pharmaceuticals, Inc. | Systemic purine administration: modulating axonal outgrowth of central nervous system neurons |
WO2010075298A2 (en) | 2008-12-23 | 2010-07-01 | Surmodics Pharmaceuticals, Inc. | Implantable composites and compositions comprising releasable bioactive agents |
US20100168807A1 (en) * | 2008-12-23 | 2010-07-01 | Burton Kevin W | Bioactive terpolymer compositions and methods of making and using same |
US8951546B2 (en) * | 2008-12-23 | 2015-02-10 | Surmodics Pharmaceuticals, Inc. | Flexible implantable composites and implants comprising same |
US9415197B2 (en) * | 2008-12-23 | 2016-08-16 | Surmodics, Inc. | Implantable suction cup composites and implants comprising same |
US8974808B2 (en) * | 2008-12-23 | 2015-03-10 | Surmodics, Inc. | Elastic implantable composites and implants comprising same |
US9480643B2 (en) * | 2008-12-23 | 2016-11-01 | Surmodics Pharmaceuticals, Inc. | Implantable composites and implants comprising same |
US20100216948A1 (en) * | 2009-01-23 | 2010-08-26 | Tipton Arthur J | Polymer mixtures comprising polymers having different non-repeating units and methods for making and using same |
WO2010085609A2 (en) * | 2009-01-23 | 2010-07-29 | Surmodics Pharmaceuticals, Inc. | Controlled release systems from polymer blends |
JP2012515790A (ja) * | 2009-01-23 | 2012-07-12 | サーモディクス ファーマシューティカルズ, インコーポレイテッド | 微粒子製造のための連続二重エマルジョン工程 |
JP2013530223A (ja) * | 2010-07-01 | 2013-07-25 | コバリス,インコーポレイテッド | 集束音響を用いたナノ製剤を調製するための組成物および方法並びにナノ送達用のシステム |
US9598532B2 (en) | 2010-08-30 | 2017-03-21 | Surmodics, Inc. | Terpolymers as pressure-sensitive adhesives |
JP2014505585A (ja) * | 2010-12-23 | 2014-03-06 | エボニック コーポレイション | エマルジョンを製造するための装置および方法 |
SG10201602665UA (en) | 2011-04-05 | 2016-05-30 | Edge Therapeutics | Intraventricular Drug Delivery System For Improving Outcome After A Brain Injury Affecting Cerebral Blood Flow |
US9399019B2 (en) | 2012-05-09 | 2016-07-26 | Evonik Corporation | Polymorph compositions, methods of making, and uses thereof |
EP2916825A1 (en) | 2012-11-09 | 2015-09-16 | Evonik Corporation | Drying methods for tuning microparticle properties |
US9439864B2 (en) | 2014-07-07 | 2016-09-13 | Antriabio, Inc. | Solvent extraction from biodegradable microparticles |
JP5801974B1 (ja) * | 2015-02-12 | 2015-10-28 | 株式会社Nextコロイド分散凝集技術研究所 | 多層エマルションの製造方法、及びカプセルの製造方法 |
US20170239240A1 (en) | 2016-02-23 | 2017-08-24 | Biodelivery Sciences International, Inc. | Sustained Release Buprenorphine Microshperes (SRBM) and Methods of Use Thereof |
CA3022693A1 (en) * | 2016-05-16 | 2017-11-23 | Amag Pharmaceuticals, Inc. | Polymeric extended release compositions of hydroxyprogesterone caproate and methods of using same |
GB201615066D0 (en) | 2016-09-06 | 2016-10-19 | Ge Healthcare Bioprocess R&D Ab | Packed bed emulsification |
GB2555658A (en) * | 2016-11-01 | 2018-05-09 | Cambridge Consultants | Microparticle production |
GB201622024D0 (en) * | 2016-11-14 | 2017-02-08 | Inventage Lab Inc | Apparatus and method for large scale production of monodisperse, microsheric and biodegradable polymer-based drug delivery |
EP3713545A1 (en) | 2017-11-22 | 2020-09-30 | Dauntless 1, Inc. | Therapeutic compound formulations |
DE102019104646A1 (de) * | 2018-02-26 | 2019-08-29 | Adelheid Holzmann | Verfahren zum Betreiben einer Verbrennungskraftmaschine, eine Anordnung zur Durchführung des Verfahrens zum Betreiben einer Verbrennungskraftmaschine und eine Vorrichtung zur Erzeugung einer Emulsion |
WO2020236950A1 (en) | 2019-05-21 | 2020-11-26 | Dauntless 1, Inc. | Therapeutic microsphere formulations containing charged polymers |
WO2020236957A1 (en) | 2019-05-21 | 2020-11-26 | Dauntless 1, Inc. | Therapeutic microsphere formulations containing end-capped polymers |
IL294641A (en) | 2019-10-31 | 2022-09-01 | Evonik Operations Gmbh | A process for preparing nanoparticles or microparticles containing a carrier polymer and one or more biologically active components |
WO2024074585A2 (en) | 2022-10-05 | 2024-04-11 | Mireca Medicines Gmbh | MICROPARTICLE AND IMPLANT FORMULATIONS FOR cGMP ANALOG THERAPY |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3780195A (en) * | 1969-10-22 | 1973-12-18 | Balchem Corp | Encapsulation process |
US3664963A (en) * | 1969-10-22 | 1972-05-23 | Balchem Corp | Encapsulation process |
DE2059494B2 (de) * | 1970-12-03 | 1972-03-16 | Licentia Gmbh | Biegsamer hohlleiter |
JPS523342B2 (zh) * | 1972-01-26 | 1977-01-27 | ||
US3865352A (en) * | 1973-11-16 | 1975-02-11 | Minnesota Mining & Mfg | Static mixing device |
DE2604832A1 (de) * | 1976-02-07 | 1977-08-11 | Basf Ag | Verfahren zur analyse von loesungen |
US4171981A (en) * | 1977-04-29 | 1979-10-23 | The Mead Corporation | Process for the production of hot melt coating compositions containing microcapsules |
US4183681A (en) * | 1978-05-19 | 1980-01-15 | Exxon Research & Engineering Co. | Emulsion preparation method using a packed tube emulsifier |
US4299501A (en) * | 1979-08-10 | 1981-11-10 | Ortho Pharmaceutical Corporation | Continuous process for the preparation of semisolid dispersions |
US4384975A (en) * | 1980-06-13 | 1983-05-24 | Sandoz, Inc. | Process for preparation of microspheres |
US4933105A (en) * | 1980-06-13 | 1990-06-12 | Sandoz Pharm. Corp. | Process for preparation of microspheres |
US4389330A (en) * | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
US4501501A (en) * | 1983-03-04 | 1985-02-26 | E. I. Du Pont De Nemours And Company | Process for dispersing solids in liquid media |
US4897268A (en) * | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
GB2209937B (en) * | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
DE3732370A1 (de) | 1987-09-25 | 1989-04-06 | Hoechst Ag | Verfahren zur vermischung von lebenden zellen oder mikroorganismen mit einer viskosen fluessigkeit und mischungen, die nach diesem verfahren hergestellt wurden |
ES2084698T5 (es) | 1989-05-04 | 2005-03-01 | Southern Research Institute | Procedimiento de encapsulacion. |
US5538739A (en) * | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
PH30995A (en) * | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
US5112604A (en) * | 1989-09-01 | 1992-05-12 | Riker Laboratories, Inc. | Oral suspension formulation |
MY107937A (en) * | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
FR2660556B1 (fr) | 1990-04-06 | 1994-09-16 | Rhone Poulenc Sante | Microspheres, leur procede de preparation et leur utilisation. |
US6120805A (en) * | 1990-04-06 | 2000-09-19 | Rhone-Poulenc Rorer Sa | Microspheres, process for their preparation and their use |
US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
NZ260909A (en) * | 1993-07-05 | 1995-04-27 | Takeda Chemical Industries Ltd | Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution |
EP2283821A1 (en) | 1993-11-19 | 2011-02-16 | Alkermes, Inc. | Preparation of biodegradable microparticles containing a biologically active agent |
GB9412273D0 (en) * | 1994-06-18 | 1994-08-10 | Univ Nottingham | Administration means |
WO1997004747A1 (en) | 1995-07-27 | 1997-02-13 | Dunn James M | Drug delivery systems for macromolecular drugs |
US5629277A (en) * | 1995-10-04 | 1997-05-13 | William L. Brown | Paint removing composition |
US6140040A (en) * | 1995-10-06 | 2000-10-31 | Advanced Minerals Corporation | Method of mechanically separating microparticles suspended in fluids using particulate media |
EP0799616A1 (en) * | 1996-04-01 | 1997-10-08 | Takeda Chemical Industries, Ltd. | Oral composition comprising a fumagillol derivative |
US5792477A (en) * | 1996-05-07 | 1998-08-11 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
JPH10109024A (ja) | 1996-10-04 | 1998-04-28 | Jasco Corp | エマルション調整方法及び装置 |
WO1998032423A1 (en) | 1997-01-29 | 1998-07-30 | Takeda Chemical Industries, Ltd. | Sustained-release microspheres, their production and use |
JPH10273447A (ja) | 1997-01-29 | 1998-10-13 | Takeda Chem Ind Ltd | 徐放性マイクロスフィア、その製造法および用途 |
SE9701161D0 (sv) | 1997-03-27 | 1997-03-27 | Karolinska Innovations Ab | New use I |
AR012448A1 (es) * | 1997-04-18 | 2000-10-18 | Ipsen Pharma Biotech | Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada |
CA2314934C (en) * | 1997-12-16 | 2006-08-29 | Chiron Corporation | Use of microparticles combined with submicron oil-in-water emulsions |
US6740634B1 (en) | 1998-01-16 | 2004-05-25 | Takeda Chemical Industries, Ltd. | Sustained release compositions, process for producing the same and utilization thereof |
JPH11349688A (ja) | 1998-06-05 | 1999-12-21 | Reika Kogyo Kk | 徐放性複合エマルション、徐放性微粒子及びその製造方法 |
US6270700B1 (en) * | 1998-07-23 | 2001-08-07 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Encapsulation of water soluble peptides |
JP3012608B1 (ja) | 1998-09-17 | 2000-02-28 | 農林水産省食品総合研究所長 | マイクロチャネル装置及び同装置を用いたエマルションの製造方法 |
US6194006B1 (en) * | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
EP1044683A1 (en) | 1999-04-15 | 2000-10-18 | Debio Recherche Pharmaceutique S.A. | One-step dispersion method for the microencapsulation of water soluble substances |
US6291013B1 (en) * | 1999-05-03 | 2001-09-18 | Southern Biosystems, Inc. | Emulsion-based processes for making microparticles |
US7919119B2 (en) * | 1999-05-27 | 2011-04-05 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
CA2386654A1 (en) * | 1999-10-08 | 2001-04-19 | The Procter & Gamble Company | Apparatus and process for in-line preparation of hipes |
JP3303856B2 (ja) | 1999-10-12 | 2002-07-22 | 松下電器産業株式会社 | 液晶表示パネルと製造方法 |
US6495166B1 (en) | 1999-11-12 | 2002-12-17 | Alkermes Controlled Therapeutics Inc. | Apparatus and method for preparing microparticles using in-line solvent extraction |
AUPQ529000A0 (en) * | 2000-01-28 | 2000-02-17 | Research Laboratories Of Australia Pty Ltd | Toner characterization cell |
US6953593B2 (en) * | 2000-02-01 | 2005-10-11 | Lipoprotein Technologies, Inc. | Sustained-release microencapsulated delivery system |
US6264987B1 (en) * | 2000-05-19 | 2001-07-24 | Alkermes Controlled Therapeutics Inc. Ii | Method for preparing microparticles having a selected polymer molecular weight |
US6306423B1 (en) * | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
US6565873B1 (en) | 2000-10-25 | 2003-05-20 | Salvona Llc | Biodegradable bioadhesive controlled release system of nano-particles for oral care products |
ATE537845T1 (de) * | 2000-10-31 | 2012-01-15 | Pr Pharmaceuticals Inc | Verfahren zur herstellung von formulierungen zur verbesserten abgabe von bioaktiven molekülen |
JP2004525403A (ja) | 2001-01-15 | 2004-08-19 | スリーエム イノベイティブ プロパティズ カンパニー | 可視波長領域における透過が高く、かつ平滑な多層赤外反射フィルム、およびそれから製造される積層物品 |
CA2435415A1 (en) | 2001-01-26 | 2002-08-01 | Debio Recherche Pharmaceutique S.A. | Microparticles of biodegradable polymer encapsulating a biologically active substance |
TWI332407B (en) | 2001-06-29 | 2010-11-01 | Takeda Chemical Industries Ltd | Controlled release composition and method of producting the same |
WO2003092585A2 (en) * | 2002-05-02 | 2003-11-13 | Pr Pharmaceuticals, Inc. | Controlled release compositions of estradiol metabolites |
EP1829529A1 (en) | 2002-05-03 | 2007-09-05 | PR Pharmaceuticals, Inc. | Controlled release compositions of estradiol metabolites |
CN1938040A (zh) * | 2003-03-05 | 2007-03-28 | Pr药品有限公司 | 缩宫素控释制剂及其应用方法 |
US20070207211A1 (en) * | 2003-04-10 | 2007-09-06 | Pr Pharmaceuticals, Inc. | Emulsion-based microparticles and methods for the production thereof |
BRPI0409032A (pt) | 2003-04-10 | 2006-05-02 | Pr Pharmaceuticals | método para a produção de micropartìculas à base de emulsão |
EP1613272B1 (en) | 2003-04-11 | 2013-12-18 | Antriabio, Inc. | Method for preparation of site-specific protein conjugates |
US8871269B2 (en) * | 2003-07-15 | 2014-10-28 | Evonik Corporation | Method for the preparation of controlled release formulations |
BRPI0412211A (pt) * | 2003-07-23 | 2006-08-22 | Pr Pharmaceuticals Inc | composições de liberação controlada |
-
2004
- 2004-04-12 BR BRPI0409032-2A patent/BRPI0409032A/pt active Search and Examination
- 2004-04-12 ES ES04750117T patent/ES2427092T3/es not_active Expired - Lifetime
- 2004-04-12 JP JP2006532408A patent/JP2007515392A/ja active Pending
- 2004-04-12 EP EP12159499A patent/EP2548550A1/en not_active Withdrawn
- 2004-04-12 AU AU2004253853A patent/AU2004253853B2/en not_active Expired
- 2004-04-12 PT PT47501176T patent/PT1615959E/pt unknown
- 2004-04-12 EP EP04750117.6A patent/EP1615959B1/en not_active Expired - Lifetime
- 2004-04-12 CA CA2516107A patent/CA2516107C/en not_active Expired - Lifetime
- 2004-04-12 CN CN201110028030XA patent/CN102166192B/zh not_active Expired - Lifetime
- 2004-04-12 WO PCT/US2004/011485 patent/WO2005003180A2/en active Application Filing
- 2004-04-12 CN CN2004800084088A patent/CN101410174B/zh not_active Expired - Lifetime
- 2004-04-12 US US10/553,003 patent/US8916196B2/en active Active
-
2009
- 2009-12-25 JP JP2009296315A patent/JP5377277B2/ja not_active Expired - Lifetime
-
2013
- 2013-01-28 JP JP2013013176A patent/JP2013136591A/ja active Pending
-
2014
- 2014-11-14 US US14/541,328 patent/US10272044B2/en active Active
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8900636B2 (en) | 2003-07-23 | 2014-12-02 | Evonik Corporation | Controlled release compositions |
CN102985175A (zh) * | 2009-12-22 | 2013-03-20 | 赢创德固赛有限公司 | 用于制备微粒的基于乳液的工艺以及供所述工艺使用的工作头组件 |
CN102985175B (zh) * | 2009-12-22 | 2016-03-09 | 赢创有限公司 | 用于制备微粒的基于乳液的工艺以及供所述工艺使用的工作头组件 |
CN111050809A (zh) * | 2017-07-10 | 2020-04-21 | 百深公司 | 孵育液体和灭活病毒的方法 |
CN111050809B (zh) * | 2017-07-10 | 2021-12-24 | 武田药品工业株式会社 | 孵育液体和灭活病毒的方法 |
CN111051381A (zh) * | 2017-09-03 | 2020-04-21 | 赢创运营有限公司 | 用于增材制造的生物相容聚合物粉末 |
KR20200049832A (ko) * | 2017-09-03 | 2020-05-08 | 에보니크 오퍼레이션즈 게엠베하 | 적층 가공을 위한 생체적합성 중합체 분말 |
KR102645701B1 (ko) | 2017-09-03 | 2024-03-12 | 에보니크 오퍼레이션즈 게엠베하 | 적층 가공을 위한 생체적합성 중합체 분말 |
Also Published As
Publication number | Publication date |
---|---|
CN102166192B (zh) | 2013-09-25 |
EP1615959A2 (en) | 2006-01-18 |
US20070190154A1 (en) | 2007-08-16 |
WO2005003180A3 (en) | 2009-04-02 |
BRPI0409032A (pt) | 2006-05-02 |
JP2010120948A (ja) | 2010-06-03 |
US8916196B2 (en) | 2014-12-23 |
EP1615959A4 (en) | 2009-11-25 |
ES2427092T3 (es) | 2013-10-28 |
CA2516107A1 (en) | 2005-01-13 |
JP2013136591A (ja) | 2013-07-11 |
PT1615959E (pt) | 2013-08-29 |
EP2548550A1 (en) | 2013-01-23 |
AU2004253853B2 (en) | 2010-04-01 |
US20150072928A1 (en) | 2015-03-12 |
CN102166192A (zh) | 2011-08-31 |
EP1615959B1 (en) | 2013-06-05 |
CA2516107C (en) | 2013-12-24 |
WO2005003180A2 (en) | 2005-01-13 |
JP5377277B2 (ja) | 2013-12-25 |
US10272044B2 (en) | 2019-04-30 |
CN101410174B (zh) | 2011-04-06 |
AU2004253853A1 (en) | 2005-01-13 |
JP2007515392A (ja) | 2007-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101410174B (zh) | 一种用于生产基于乳化的微观粒子的方法 | |
Liu et al. | Preparation of uniform-sized multiple emulsions and micro/nano particulates for drug delivery by membrane emulsification | |
Mishima | Biodegradable particle formation for drug and gene delivery using supercritical fluid and dense gas | |
US20190240630A1 (en) | Apparatus and methods for preparing an emulsion | |
CN1953803B (zh) | 标准生物可降解微球体的制备方法 | |
Patel et al. | Microsphere as a novel drug delivery. | |
US20070207211A1 (en) | Emulsion-based microparticles and methods for the production thereof | |
Gasparini et al. | Preparation and characterization of PLGA particles for subcutaneous controlled drug release by membrane emulsification | |
Cheng et al. | A simple method for the preparation of monodisperse protein-loaded microspheres with high encapsulation efficiencies | |
NO302683B1 (no) | Emulsjonsbasert fremgangsmåte for mikroinnkapsling av et middel | |
Luo et al. | Well-designed microcapsules fabricated using droplet-based microfluidic technique for controlled drug release | |
JP2004035446A (ja) | 微小球体の製造方法およびその製造装置 | |
US20080260852A1 (en) | Supercritical fluid extraction produced by in-line homogenization | |
EP1847261A1 (en) | Assembly of devices used for the production of microcapsules for the controlled release of peptides | |
Richard et al. | Supercritical fluid processes for polymer particle engineering | |
Muhrer | Gas antisolvent recrystallization of specialty chemicals | |
CN111315365A (zh) | 用于通过双乳液技术制备微粒的方法 | |
SA | JOEL RICHARD Ethypharm SA, Saint-Cloud, France | |
Wang | Development of supercritical fluid processes for particle coating/encapsulation with polymers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: EVONIK LTD. Free format text: FORMER OWNER: SURMODICS SMP INC. Effective date: 20130916 Owner name: BROOKWOOD PHARMACEUTICALS INC. Free format text: FORMER OWNER: PR PHARMACEUTICALS, INC. Effective date: 20130916 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: PR PHARMACEUTICALS INC. Free format text: FORMER NAME: BROOKWOOD PHARMACEUTICALS INC. Owner name: SURMODICS SMP INC. Free format text: FORMER NAME: PR PHARMACEUTICALS INC. |
|
CP01 | Change in the name or title of a patent holder |
Address after: American Delaware Patentee after: PR PHARMACEUTICALS, Inc. Address before: American Delaware Patentee before: Brooke Wood pharmaceuticals Ltd. |
|
CP03 | Change of name, title or address |
Address after: American Minnesota Patentee after: Sur Modi Kors SMP Address before: American Delaware Patentee before: PR PHARMACEUTICALS, Inc. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130916 Address after: American New Jersey Patentee after: Evonik Corp. Address before: American Minnesota Patentee before: Sur Modi Kors SMP Effective date of registration: 20130916 Address after: American Delaware Patentee after: Brooke Wood pharmaceuticals Ltd. Address before: American Colorado Patentee before: PR Pharmaceuticals, Inc. |
|
CX01 | Expiry of patent term |
Granted publication date: 20110406 |
|
CX01 | Expiry of patent term |